Category
Michael Polansky’s Outer Bio launched with $23M and an unusual pitch: not a drug company, but an AI platform screening compounds on living human skin.
Johnson & Johnson pays $785 million upfront for an option to buy Flagship-backed Sail Biomedicines, whose nanoparticle-and-RNA platform aims to make CAR-T inside the body.
The all-stock reverse merger, paired with a $278 million private placement, creates a Nasdaq-listed company built around CLD-423 for inflammatory bowel disease.
Shares jumped 56% on debut as the biotech advances oxnimbi, a once-nightly pill targeting an underlying cause of obstructive sleep apnea, toward a 2027 FDA decision.
The cardiac-myosin inhibitor developer priced one of the year’s larger biotech IPOs to fund BHB-1893, a would-be rival to Bristol Myers’ Camzyos for a serious heart-muscle disease.
The company’s long-acting retina treatment failed to prove non-inferiority to standard therapy across the full trial, wiping out nearly $1 billion in market value.
The world’s largest biosimilar maker will commercialize up to 10 Henlius-developed copies of blockbuster biologics globally, positioning for one of the industry’s biggest-ever patent cliffs.
The all-stock merger of equals unites Supernus’s brain-disorder portfolio with Indivior’s addiction treatments, forming a company with 11 marketed drugs.
Prediction-market firm Kalshi has opened contracts on whether drugs will hit their endpoints or win FDA approval, raising fresh insider-trading and ethics concerns.
The drugmaker added $1 billion to its savings target and raised its 2026 revenue outlook, even as COVID sales collapse and several cancer drugs slip.
The AI-first primary-care startup adds Summer Health’s text-based pediatric service and a 100,000-message dataset to cover care ‘from birth through adulthood.’
The digital musculoskeletal-care company is expanding into gut health — a huge, underserved market — with plans for one combined app in 2027.
Adding BioLife’s cell-preservation technology to its bioprocessing tools, Repligen is betting on vertical integration as cell and gene therapies scale up.
The joint investment expands device assembly for Lilly’s KwikPen in the Cincinnati region, adding at least 400 jobs as demand for diabetes and obesity injectables surges.
A $200 million trim to sales guidance and signs that an early demand surge had normalized wiped out roughly $12 billion in market value, as competition in the heart-disease market intensifies.
Retatrutide isn’t approved anywhere — but a gray market of compounders and ‘peptide’ sellers is already hawking copies, prompting Lilly to go to court.
CEO Mike Doustdar says the obesity giant will stick to smaller ‘bolt-on’ deals after clinical setbacks and a Wegovy sales miss, amid intensifying pressure from Eli Lilly.
The startup’s AI runs virtual versions of trials to predict patient responses and flag design flaws — aiming at the industry’s roughly 90% clinical-trial failure rate.
Newly disclosed documents show Vertex was the only bidder left standing after a months-long courtship of the acromegaly drugmaker.
The Venrock-led round backs a platform that lets self-funded employers contract, in one deal, with thousands of advanced primary-care practices that sit outside insurance networks.
Co-founded by Georg Schett — who showed CAR-T can drive lupus into remission — the Deerfield-backed startup aims to reset the immune system with more convenient antibodies.
NICE has backed Eli Lilly’s Onswik, a weekly insulin injection, for type 2 diabetes — cutting jabs by about 85% for patients who struggle with daily dosing, pending final approval.
The all-stock deal, paired with a $200 million raise, hands Processa a once-daily, brain-penetrating BTK inhibitor targeting food allergy, chronic urticaria and multiple sclerosis.
The Series B, led by General Atlantic, backs EXPD-101, a once-daily DPP1 inhibitor licensed from Fosun Pharma and now entering a global Phase 2 trial in COPD.
The structured financing releases cash as seralutinib hits regulatory milestones, funding the biotech through a planned NDA submission for pulmonary hypertension.
Sobi gains commercial rights to lacutamab, a first-in-class antibody for cutaneous T-cell lymphoma now in a Phase 3 confirmatory trial and heading for accelerated approval.
The deal adds gildeuretinol, a modified vitamin A in Phase 3 for Stargardt disease, to Tarsus — a program championed by Vertex founder Josh Boger.
Vertex raised guidance on $3.2B in quarterly CF sales, yet analysts are watching tiny Sionna Therapeutics, whose experimental drug could layer on top of Vertex’s Trikafta.
The Nav1.8-inhibitor developer priced at the top of its range to fund a Phase 3-ready pain drug meant to rival Vertex’s Journavx, as biotech IPOs keep rolling.
Backed by Bezos and Gates funds, the company’s fungal-genome platform yielded LIFE-001, a long-acting drug that suppresses transplant rejection while sparing the brain.
The one-time gene therapy ST-920 is heading toward an FDA filing; PTC picked it up at auction after gene-medicine pioneer Sangamo filed for bankruptcy.
Licensing HM17321 from Korea’s Hanmi, Roche is chasing the next frontier in weight loss: shedding fat while preserving the muscle that today’s GLP-1 drugs also strip away.
A Financial Times report of merger talks sent AstraZeneca stock lower as analysts questioned why the fast-growing company would take on such a deal. Neither firm has confirmed.
The partnership pairs Evotec’s AI-driven discovery platforms with Odyssey’s disease biology to find small-molecule drugs for immune-driven conditions.
Strong specialty-medicine sales lifted GSK's second quarter as the drugmaker doubles down on oncology — and braces for looming HIV patent losses.
The deal would resolve about 69,000 claims linking the company's talc baby powder to ovarian cancer — even as J&J maintains its products are safe.
The Dutch biotech will push its brain-signaling drug through a mid-stage trial for cognitive impairment in schizophrenia — a common, disabling problem with no approved treatment.
BMS will deploy Schrödinger’s new AI “co-scientist” and synthesis-planning tools alongside physics-based simulation to speed molecular design.
After shelving its sickle cell program over safety concerns, Fulcrum is combining with Slate Medicines in a reverse merger built around a next-generation migraine drug.
The multi-modality site — making small molecules, biologics and antibody-drug conjugates — is part of BMS’s $40 billion U.S. push amid tariffs and reshoring.